⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nektar Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Nektar Therapeutics
↗San Francisco, USA
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines to address high unmet medical needs in autoimmune and chronic inflammatory diseases. The company leverages its proprietary chemistry platform to develop novel therapeutic candidates that aim to resolve immune imbalances and regain immune homeostasis.
Headquartered in San Francisco, California, Nektar has a long history of research and development, transitioning from its origins in PEGylation technology to its current focus on immunology. The company maintains a robust pipeline of investigational drugs and has a track record of strategic partnerships with major pharmaceutical companies to advance its clinical programs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:1990
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:NKTR
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2b
Modalities:Biologic, Antibody, Small molecule
Trial Phases:Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Eli Lilly (NKTR-358/Rezpegaldesleukin), UCSF (NKTR-0165 research collaboration), SFJ Pharmaceuticals (Bempegaldesleukin financing)
COMPETITION
Position:Emerging
Competitors:AbbVie, Apogee Therapeutics
LEADERSHIP
Key Executives:
Howard W. Robin - President and CEO
Jonathan Zalevsky - Chief Research & Development Officer
Linda Rubinstein - Chief Financial Officer
LINKS
Website:nektar.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nektar Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.